Phase 1 clinical trial of novel HIV vaccine approach shows promising results
A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced today. The vaccine showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine.
This study demonstrates proof of principle for a new vaccine concept for HIV, a concept that could be applied to other pathogens, as well. With our many collaborators on the study team, we showed that vaccines can be designed to stimulate rare immune cells with specific properties, and this targeted stimulation can be very efficient in humans. We believe this approach will be key to making an HIV vaccine and possibly important for making vaccines against other pathogens.
Phase 1 Clinical Trial Confirms HIV Vaccine Approach by Angela Mohan on February 4, 2021 at 11:12 AM
Phase 1 clinical trial testing a novel vaccine against HIV has produced promising results, IAVI and Scripps Research announced. The vaccine showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine. This study demonstrates proof of principle for a new vaccine concept for HIV, a concept that could be applied to other pathogens, as well, says William Schief, Ph.D., a professor and immunologist at Scripps Research and executive director of vaccine design at IAVI s Neutralizing Antibody Center, whose laboratory developed the vaccine.
Loading video.
VIDEO: A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced. The vaccine showed success in stimulating production of. view more
Credit: Scripps Research
NEW YORK and LA JOLLA, CA A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced today. The vaccine showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine.